Head and Neck Cancers Coverage from Every Angle

Recent News

Fox Chase Researcher Shares NIH Grant to Study Palliative Care in Head and Neck Cancer
ASCO 2019: Targeting Resistant Adenoid Cystic Carcinoma With Apatinib
ASCO 2019: Phase II Basket Trial of T-DM1 in Salivary Gland Cancers
Pembrolizumab Approved for First-Line Treatment of Head and Neck Squamous Cell Carcinoma
ASCO 2019: Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Head and Neck Cancer
Forecasting Trends in Oropharyngeal Cancer in the United States
ASCO 2019: First-Line Pembrolizumab for Metastatic Head/Neck Cancer
Use of Acetylcysteine for Cisplatin-Induced Toxicities in Head and Neck Cancer
FDA Grants Orphan Drug Designation for AL101 in Adenoid Cystic Carcinoma
Alternative Chemotherapy Regimen to Cisplatin in Locally Advanced Head/Neck Cancer
Potential Applications of Machine Learning and Radiomics in Head and Neck Cancers
NIH Releases Latest PDQ Cancer Information Summary on Head and Neck Cancers
Phase II Study of Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
Mount Sinai Begins Clinical Trials in Head and Neck Cancers
Head and Neck Cancer’s Genetic Relationship to Other Cancers
Use of New Nomogram in Predicting Lymph Node Metastasis in Papillary Thyroid Cancer
AACR 2019: Can the Timing of Radiotherapy Affect the Severity of Oral Mucositis?
Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions
Why Are Young Nonsmokers Presenting With Glottic Carcinomas?
Use of Minimally Invasive Biopsy for Early-Stage Oral Cancer
2019 ASCO-SITC: Tumor Growth Rate and Outcomes With Nivolumab in Head and Neck Cancer
2019 ASCO-SITC Symposium: Regulatory T Cells and Treatment Resistance in Head/Neck Cancer
2019 ESMO TAT: Predicting Outcomes With Lung Immune Prognostic Index
Is Incidence of Thyroid Cancer in United States Related to Malpractice Climate?
FDA Grants Priority Review to Pembrolizumab in First-Line Therapy for Metastatic Head/Neck Cancer
Gene Mutations by Smoking Status in Head and Neck Cancer
Using Genetic Biomarker to Predict Outcome in HPV-Related Oropharyngeal Cancer
KEYNOTE-040 Supports Benefit of Pembrolizumab in Resistant Head and Neck Cancer
Oropharyngeal Cancer and Opioid Use
Phase II Durvalumab Trial in Resistant Head and Neck Cancer
Is HPV on the Rise in Oropharyngeal Cancers?
Radiotherapy Plus Chemotherapy in HPV-Positive Oropharyngeal Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.